NCT05068427 - Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

February 23, 2023

Study Completion Date

May 16, 2024

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Chidamide

20mg or 30mg orally twice per week(BIW)

DRUG

Envafolimab

400mg subcutaneous infusions every 4 weeks

Trial Locations (12)

Shanghai Chest Hospital, Shanghai

Shanghai East Hospital, Shanghai

Xuzhou Central Hospital, Xuzhou

Nantong Tumor Hospital, Nantong

The Second Hospital of Anhui Medical University, Hefei

Linyi Cancer Hospital, Linyi

Zhejiang Provincial People's Hospital, Hangzhou

Henan Cancer Center, Zhengzhou

Sun Yat-sen University Cancer Center, Guangzhou

Southern Medical University Affiliated Nanfang Hospital, Guangzhou

Guangxi Medical University Affiliated Tumor Hospital, Nanning

Baoding No.2 Central Hospital, Baoding